Abstract:Background: Pemetrexed maintenance therapy offers a survival benefit in patients with nonprogressive advanced nonsquamous non-small cell lung cancer (NSCLC) with good tolerability. This study was designed to analyze the efficacy and safety of pemetrexed maintenance chemotherapy in advanced nonsquamous NSCLC patients in a real-world setting. Methods: The response rate (RR) and adverse events in 71 nonsquamous NSCLC patients treated with pemetrexed-based chemotherapy were observed until disease progression or unacceptable toxicities. Measures of survival were analyzed during follow-up. Results: Of 69 efficacy-evaluable patients, the objective response rate (ORR) was 46.4% and the disease control rate (DCR) was 98.6%. ORR showed no significant difference between patients who received pemetrexed as first-line therapy and those who received pemetrexed as second-line or higher treatment. The median treatment cycle for all patients was 8. The median progression-free survival (PFS) was 9.5 months (m) and median overall survival (OS) was 30.5 m. The univariate and multivariate analyses showed that the number of chemotherapy cycles was an independent factor for PFS. The most common adverse reactions were grade 1 to 2 hematologic toxicities, gastrointestinal reactions, and liver enzyme abnormalities. Only 1 patient experienced a grade 3 gastrointestinal event. Conclusions: Pemetrexed maintenance chemotherapy can improve PFS in patients with advanced nonsquamous NSCLC with good tolerability. Keywords: Pemetrexed; maintenance; non-small cell lung cancer (NSCLC); progression-free survival (PFS); Background: Pemetrexed maintenance therapy offers a survival benefit in patients with nonprogressive advanced nonsquamous non-small cell lung cancer (NSCLC) with good tolerability. This study was designed to analyze the efficacy and safety of pemetrexed maintenance chemotherapy in advanced nonsquamous NSCLC patients in a real-world setting. Methods: The response rate (RR) and adverse events in 71 nonsquamous NSCLC patients treated with pemetrexed-based chemotherapy were observed until disease progression or unacceptable toxicities. Measures of survival were analyzed during follow-up. Results: Of 69 efficacy-evaluable patients, the objective response rate (ORR) was 46.4% and the disease control rate (DCR) was 98.6%. ORR showed no significant difference between patients who received pemetrexed as first-line therapy and those who received pemetrexed as second-line or higher treatment. The median treatment cycle for all patients was 8. The median progression-free survival (PFS) was 9.5 months (m) and median overall survival (OS) was 30.5 m. The univariate and multivariate analyses showed that the number of chemotherapy cycles was an independent factor for PFS. The most common adverse reactions were grade 1 to 2 hematologic toxicities, gastrointestinal reactions, and liver enzyme abnormalities. Only 1 patient experienced a grade 3 gastrointestinal event. Conclusions: Pemetrexed maintenance chemotherapy can improve PFS in patients with advanced nonsquamous NSCLC with good tolerability.

Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

A Phase I/Ii and Pharmacogenomic Study of Pemetrexed and Cisplatin in Patients with Unresectable, Advanced Gastric Carcinoma

Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

Pharmacokinetic evaluation of pemetrexed

Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy

Pd-L1 Expression Indicates Favorable Prognosis for Advanced Lung Adenocarcinoma Patients Treated with Pemetrexed

Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial

Pemetrexed plus platinum in non-small cell lung cancer:a Meta analysis of randomized controlled trials

Efficacy and Safety of Pemetrexed Maintenance Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Real-World Setting

Pemetrexed Alone Regimen in Treatment of Advanced Chemo-Recurrent Non-Small Cell Lung Cancer

Pemetrexed As the First-Line Therapy for Chinese Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer.

Survival Without Common Toxicity Criteria Grade 3/4 Toxicity Following Second-Line Treatment with Pemetrexed for Nonsquamous Non-Small Cell Lung Cancer in Chinese Patients

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients

Effect of Pemetrexed Plus Platinum for Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer

Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling